Staphylococcal Infections  >>  Cubicin (daptomycin)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cubicin (daptomycin) / Merck (MSD)
NCT00463801 / 2006-004664-31: Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections

Terminated
4
52
Europe
Daptomycin
Novartis
Staphylococcal Skin Infections
11/07
 
DAPHEOR1006, NCT01419184: Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

Completed
4
250
US
Daptomycin, Cubicin, Vancomycin
Cubist Pharmaceuticals LLC
Staphylococcal Skin Infections
09/12
10/12
NCT01196169: Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

Terminated
4
28
US
Daptomycin, Cubicin, Vancomycin
Mountain Home Research & Education Corporation, East Tennessee State University, Cubist Pharmaceuticals LLC
Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus
03/14
03/14

Download Options